Currently Viewing:
The International Society for Pharmacoeconomics and Outcomes Research
Continuing Forward With Innovation and Progress in US Healthcare
May 22, 2017
Dr Gail Wilensky: Senate Health Bill Will Be to the Left of the House
May 22, 2017
Accounting for Stakeholder Preferences in Value Assessments
May 22, 2017
Dr David M. Cutler Highlights the Importance of Reauthorizing the CHIP Program
May 22, 2017
Negotiating Successful Outcomes-Based Contracts
May 23, 2017
Dr Ilene Hollin: Tailored Approach to Value Assessment Is Necessary
May 23, 2017
Influencing Untreated Individuals Through Their Social Networks
May 23, 2017
Dr Steve Pearson Outlines the Importance of Thresholds on Determining Value
May 23, 2017
The Realities and Challenges of Medicare Negotiating Drug Prices
May 24, 2017
Currently Reading
Dr Patricia Danzon: Cost-Effectiveness Thresholds Create Incentive to Develop Better Drugs
May 24, 2017
Dr James D. Chambers Talks Future Health Economics Trends He Is Watching
May 24, 2017
Dr Gail Wilensky Remains "Hopeful" for Bipartisan Legislation on Healthcare Reform
May 29, 2017
Dr David Cutler: Won't Be Easy for Senate Republicans to Create a Healthcare Bill
May 30, 2017
Not Enough Attention Paid to Low Healthcare Spending Growth
June 13, 2017
Dr Steve Pearson's Outlook on the Ongoing Updates to ICER's Value Framework
June 18, 2017
Dr Scott Ramsey on Challenges of Determining Cost Effectiveness of Novel Cancer Treatments
June 19, 2017
Dr David Cutler Discusses Opportunities for Bipartisan ACA Reform
June 20, 2017
Dr Steve Pearson Explains How ICER Price Benchmarks Align Cost With Patient Benefits
June 22, 2017
Dr Gail Wilensky Raises Questions About Medicaid's Matching Grant Structure
June 25, 2017
Dr Scott Ramsey Addresses the Need for Differential Pricing Structures for Drugs
July 02, 2017
Dr Steve Pearson: Patient Perspectives Guide ICER Value Framework Development
July 04, 2017
Dr Gail Wilensky on the Likelihood of Continuing Value-Based Reimbursement Demonstrations
July 06, 2017
Dr David Cutler: Trump Administration's Attention Not on Value-Based Purchasing
July 09, 2017
Dr Steve Pearson on Data Needed to Evaluate Clinical and Economic Effects of New Therapies
July 14, 2017

Dr Patricia Danzon: Cost-Effectiveness Thresholds Create Incentive to Develop Better Drugs

Cost-effectiveness thresholds can do more than just guide determinations on whether drugs have value, explained Patricia Danzon, PhD, professor at the Wharton School at the University of Pennsylvania. Using these thresholds as a requirement for reimbursement provides an incentive for research and development focused on producing new drugs that will be considered effective enough to pay for.


Cost-effectiveness thresholds can do more than just guide determinations on whether drugs have value, explained Patricia Danzon, PhD, professor at the Wharton School at the University of Pennsylvania. Using these thresholds as a requirement for reimbursement provides an incentive for research and development (R&D) focused on producing new drugs that will be considered effective enough to pay for.

Transcript (slightly modified)

How can attempts to be mindful of cost and budget be balanced with fostering innovation in the US?

When we set a threshold for what is considered a reasonable about to pay per QALY, and let’s say we pick $150,000 per quality-adjusted life year, that amount is picked taking into account what we as a society are willing to pay for health gain, given what we have to give up, the opportunity cost in terms of non-health activities, so whether it’s education or Social Security or other things.

Then, given that threshold, any product that can meet that threshold, we should be willing to pay for. So there is an incentive to R&D to produce drugs that produce effectiveness and cost savings such that they meet that threshold. If we base our prices on that cost-effectiveness threshold, we create an incentive to steer R&D towards the sort of products that will produce drugs that are cost-effective.

That’s the way in which, if we really do use cost-effectiveness as a way of rewarding drugs that do meet that threshold, we are creating an incentive to produce drugs that will meet the threshold and therefore will get reimbursed, whereas if products are priced either above the threshold or don’t have much in the way of efficacy and safety, then they would not be worth it, they would not be considered cost-effective, and that would not be a good investment. Hopefully, by our reimbursement strategy, we’re sending the signals to R&D on what is worth investing in.

 
Copyright AJMC 2006-2020 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
x
Welcome the the new and improved AJMC.com, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up